CLRB Live signals | Maximize Profits with Getagraph.com

SELL 105618 min ago

@ $3.47

Issued: 13 Feb 2024 @ 11:14

Return: -12.68%

Previous signal: Feb 7 - 09:31

Previous signal: Buy

Return: -0.86 %

Live Chart Being Loaded With Signals

Commentary (26 Apr 2024 @ 16:00):

Cellectar Biosciences, Inc., a clinical biopharmaceutical company, focuses on the discovery, development, and commercialization of drugs for the treatment of cancer...

Stats
Today's Volume	686 302
Average Volume	1.08M
Market Cap	97.75M
EPS	$0 ( 2024-03-27 )
Next earnings date	( $-0.500 ) 2024-05-02
Last Dividend	$0 ( N/A )
Next Dividend	$0 ( N/A )
P/E	-0.970
ATR14	$0.00600 (0.20%)

Insider Trading

Date	Person	Action	Amount	type
2023-06-23	Lea Darrell Shane	Buy	100 000	Stock option (right to buy)
2023-12-08	Lea Darrell Shane	Buy	39 599	Common Stock
2023-06-23	Kolean Chad J	Buy	104 000	Stock option (right to buy)
2023-12-08	Kolean Chad J	Buy	42 554	Common Stock
2023-12-08	Shustov Andrei	Buy	47 856	Common Stock

INSIDER POWER
100.00
Last 93 transactions
Buy: 8 845 700 \| Sell: 235 734

Volume Correlation

Long: -0.16 (neutral)

Short: -0.84 (strong negative)

Signal:(34.674) Neutral

Cellectar Biosciences Inc Correlation

10 Most Positive Correlations
CNTX	0.857
AIP	0.849
AMWD	0.841
PLAB	0.841
AMTX	0.832
RCMT	0.831
EBIX	0.825
PRIM	0.824
CSWI	0.822
JSML	0.818

10 Most Negative Correlations
AMRB	-0.847
NVEI	-0.809

Did You Know?

Correlation is a statistical measure that describes the relationship between two variables. It ranges from -1 to 1, where -1 indicates a perfect negative correlation (as one variable increases, the other decreases), 1 indicates a perfect positive correlation (as one variable increases, the other increases), and 0 indicates no correlation (there is no relationship between the variables).

Correlation can be used to analyze the relationship between any two variables, not just stocks. It's commonly used in fields such as finance, economics, psychology, and more.

Cellectar Biosciences Inc Correlation - Currency/Commodity

0.24
( neutral )

-0.22
( neutral )

0.00
( neutral )

0.33
( neutral )

0.00
( neutral )

0.14
( neutral )

Cellectar Biosciences Inc Financials

Annual	2023
Revenue:	$0
Gross Profit:	$-192 375 (0.00 %)
EPS:	$-3.11

FY	2023
Revenue:	$0
Gross Profit:	$-192 375 (0.00 %)
EPS:	$-3.11

FY	2022
Revenue:	$0
Gross Profit:	$-238 867 (0.00 %)
EPS:	$-4.05

FY	2021
Revenue:	$0.00
Gross Profit:	$0.00 (0.00 %)
EPS:	$-4.30

Financial Reports:

No articles found.

Cellectar Biosciences Inc

Cellectar Biosciences, Inc., a clinical biopharmaceutical company, focuses on the discovery, development, and commercialization of drugs for the treatment of cancer. Its lead phospholipid drug conjugate (PDC) candidate is CLR 131 (iopofosine I-131), which is in Phase 2 clinical study in patients with relapsed or refractory (r/r) Waldenstrom's macroglobulinemia and B-cell malignancies; Phase 2B clinical study in r/r multiple myeloma (MM) patients; and Phase I study for various pediatric cancers, r/r head and neck cancers, and R/R MM. The company also develops CLR 1900, a PDC chemotherapeutic program that is in the preclinical development stage to treat solid tumors. It has collaborative PDC programs with Avicenna Oncology GMBH to develop CLR 2000 Series; Orano Med to develop CLR 12120 Series; IntoCell Inc; and LegoChemBio. The company was founded in 2002 and is headquartered in Florham Park, New Jersey.

Realtime updates for Cellectar Biosciences Inc [CLRB]

Upcoming Earnings Alert